ANI Pharmaceuticals, Inc. (ANIP): Price and Financial Metrics


ANI Pharmaceuticals, Inc. (ANIP): $27.22

-0.17 (-0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANIP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

ANIP POWR Grades


  • ANIP scores best on the Growth dimension, with a Growth rank ahead of 83% of US stocks.
  • The strongest trend for ANIP is in Momentum, which has been heading down over the past 47 weeks.
  • ANIP ranks lowest in Quality; there it ranks in the 10th percentile.

ANIP Stock Summary

  • Price to trailing twelve month operating cash flow for ANIP is currently 26.51, higher than 79.07% of US stocks with positive operating cash flow.
  • Of note is the ratio of Ani Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; 25.85% of US stocks have a lower such ratio.
  • The volatility of Ani Pharmaceuticals Inc's share price is greater than that of only 17.65% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ani Pharmaceuticals Inc are VIPS, TTMI, CCMP, EHTH, and DHX.
  • ANIP's SEC filings can be seen here. And to visit Ani Pharmaceuticals Inc's official web site, go to www.anipharmaceuticals.com.

ANIP Valuation Summary

  • In comparison to the median Healthcare stock, ANIP's EV/EBIT ratio is 285.67% lower, now standing at -54.4.
  • Over the past 243 months, ANIP's price/sales ratio has gone NA NA.
  • ANIP's price/earnings ratio has moved down 8.8 over the prior 243 months.

Below are key valuation metrics over time for ANIP.

Stock Date P/S P/B P/E EV/EBIT
ANIP 2021-08-31 1.8 2.0 -22.5 -54.4
ANIP 2021-08-30 1.6 1.8 -20.3 -50.8
ANIP 2021-08-27 1.7 1.9 -20.7 -51.4
ANIP 2021-08-26 1.6 1.8 -20.4 -50.9
ANIP 2021-08-25 1.7 1.9 -20.8 -51.6
ANIP 2021-08-24 1.7 1.9 -21.5 -52.7

ANIP Growth Metrics

  • Its 5 year revenue growth rate is now at 156.46%.
  • Its 2 year revenue growth rate is now at 8.96%.
  • The 5 year cash and equivalents growth rate now stands at -83.16%.
ANIP's revenue has moved up $21,637,000 over the prior 33 months.

The table below shows ANIP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 213.377 13.586 -17.221
2021-03-31 213.222 34.225 -15.451
2020-12-31 208.475 15.267 -22.548
2020-09-30 199.189 25.779 -23.748
2020-06-30 197.547 49.186 -20.287
2020-03-31 203.434 33.05 -1.366

ANIP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANIP has a Quality Grade of D, ranking ahead of 10.54% of graded US stocks.
  • ANIP's asset turnover comes in at 0.457 -- ranking 99th of 677 Pharmaceutical Products stocks.
  • EGRX, NAII, and CBIO are the stocks whose asset turnover ratios are most correlated with ANIP.

The table below shows ANIP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.457 0.592 -0.029
2021-03-31 0.460 0.600 -0.018
2020-12-31 0.446 0.582 -0.047
2020-09-30 0.427 0.596 -0.063
2020-06-30 0.425 0.619 -0.054
2020-03-31 0.442 0.655 0.014

ANIP Price Target

For more insight on analysts targets of ANIP, see our ANIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.00 Average Broker Recommendation 1.75 (Moderate Buy)

ANIP Stock Price Chart Interactive Chart >

Price chart for ANIP

ANIP Price/Volume Stats

Current price $27.22 52-week high $40.00
Prev. close $27.39 52-week low $23.55
Day low $26.57 Volume 17,517
Day high $27.35 Avg. volume 57,476
50-day MA $30.74 Dividend yield N/A
200-day MA $31.88 Market Cap 347.38M

ANI Pharmaceuticals, Inc. (ANIP) Company Bio


ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company was founded in 2004 and is based in Baudette, Minnesota.


ANIP Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIP Latest Social Stream


Loading social stream, please wait...

View Full ANIP Social Stream

Latest ANIP News From Around the Web

Below are the latest news stories about Ani Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANIP as an investment opportunity.

Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Shareholder Ownership Skewed Towards Insiders?

If you want to know who really controls ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ), then you'll have to look at the...

Yahoo | September 3, 2021

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin® Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review. FDAs acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ

Business Wire | August 31, 2021

ANI Pharmaceuticals Says Its Supplemental NDA For Purified Cortrophin Gel Accepted

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Tuesday said the FDA has accepted the company''s supplemental New Drug Application for Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. A decision by the FDA on the application is expected on October 29, 2021.

Business Insider Markets | August 31, 2021

ANI Pharmaceuticals Reports Second Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021. Second Quarter and Recent Business Highlights: The Company refiled its supplemental new drug application (sNDA) for Cortrophin® Gel with the U.S. Food and Drug Administration (FDA or the Agency) on June 29, 2021; goal date is October 29, 2021; Acquisition of Novitium Pharma LLC (Novi

Business Wire | August 6, 2021

ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript

ANIP earnings call for the period ending June 30, 2021.

The Motley Fool | August 6, 2021

Read More 'ANIP' Stories Here

ANIP Price Returns

1-mo -4.49%
3-mo -17.44%
6-mo -20.71%
1-year -7.70%
3-year -48.64%
5-year -57.67%
YTD -6.27%
2020 -52.91%
2019 36.98%
2018 -30.15%
2017 6.32%
2016 34.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0039 seconds.